» Articles » PMID: 11081893

Relaxation Induced by CGMP Phosphodiesterase Inhibitors Sildenafil and Zaprinast in Human Vessels

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2000 Nov 18
PMID 11081893
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sildenafil is currently used in the treatment of erectile dysfunction. However, assessment of direct effects of sildenafil on coronary arteries and on arteries used as coronary grafts is unknown. This study was designed to investigate the effects of sildenafil on contracted human coronary, internal mammary, and radial arteries obtained from multiorgan donors. The observations were extended to forearm veins. Zaprinast was included in this study for comparison.

Methods: Segments of left coronary, internal mammary, and radial arteries, and forearm veins were obtained from 16 multiorgan donors. Vascular rings were suspended in organ bath chambers and isometric tension was recorded. Then the effects of sildenafil, zaprinast, and sodium nitroprusside on precontracted vessels were studied.

Results: Sildenafil (10(-8) - 3 x 10(-5) mol/L) caused concentration-dependent relaxation in the internal mammary arteries, radial arteries, and forearm veins. In the coronary arteries, sildenafil had a modest relaxant effect. In addition, sildenafil amplified the relaxation induced by sodium nitroprusside in all four vessels. Relaxation was unaffected by the inhibitor of nitric oxide synthase NG-monomethyl-L-arginine (10(-4) mol/L). Compared with zaprinast, sildenafil was eight to ten times more potent in terms of EC50 values.

Conclusions: The direct relaxant effects of sildenafil together with its synergistic interaction with nitric oxide donors should be considered in patients undergoing coronary bypass surgery, patients with low blood pressure, and patients receiving antihypertensive regimes.

Citing Articles

Analysis of Geometric and Hemodynamic Profiles in Rat Arteriovenous Fistula Following PDE5A Inhibition.

Northrup H, Somarathna M, Corless S, Falzon I, Totenhagen J, Lee T Front Bioeng Biotechnol. 2021; 9:779043.

PMID: 34926425 PMC: 8675087. DOI: 10.3389/fbioe.2021.779043.


Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

Peuler J, Phelps L J Smooth Muscle Res. 2015; 51:22-36.

PMID: 26004378 PMC: 5137313. DOI: 10.1540/jsmr.51.22.


Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.

Tandon P, Inayat I, Tal M, Spector M, Shea M, Groszmann R Clin Gastroenterol Hepatol. 2010; 8(6):546-9.

PMID: 20144739 PMC: 2879450. DOI: 10.1016/j.cgh.2010.01.017.


Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension.

Wang Y, Lin H, Yang Y, Hou M, Lee S J Gastroenterol. 2006; 41(6):593-7.

PMID: 16868809 DOI: 10.1007/s00535-006-1809-y.


Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil.

Dietz U, Tries H, Merkle W, Jaursch-Hancke C, Lambertz H Cardiovasc Diabetol. 2003; 2:8.

PMID: 12952551 PMC: 194431. DOI: 10.1186/1475-2840-2-8.